source
- Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug marketThe American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
- City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt diseaseCity Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…